The intrarenal renin-angiotensin and dopaminergic systems: Control of renal sodium excretion and blood pressure

Hypertension

Volumn 61, Issue 3, 2013, Pages 673-680

  Carey, Robert M ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE; DOPAMINE; ENDOTHELIN; MESSENGER RNA; PROTEIN TYROSINE PHOSPHATASE; SARALASIN; SODIUM; VASOPRESSIN;

BLOOD PRESSURE; CELL MEMBRANE; CONFERENCE PAPER; DOPAMINERGIC SYSTEM; ENZYME ACTIVATION; GLOMERULUS FILTRATION RATE; HUMAN; INTRACELLULAR SIGNALING; KIDNEY BLOOD FLOW; KIDNEY PROXIMAL TUBULE; NATRIURESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RECEPTOR BINDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM ABSORPTION; SODIUM URINE LEVEL; VASOCONSTRICTION;

ANIMALS; BLOOD PRESSURE; DOPAMINERGIC NEURONS; FEMALE; HUMANS; KIDNEY; MALE; MICE; RATS; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, DOPAMINE D1; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; SODIUM; VASODILATION;

EID: 84874376269     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.00241     Document Type: Conference Paper

References (76)

1. Carey RM, Siragy HM. Newly recognized components of the reninangiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev. 2003;24:261-271.
2. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52:415-472.
3. Carey RM. Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age. Hypertension. 2005;45:840-844.
4. Jones ES, Vinh A, McCarthy CA, Gaspari TA, Widdop RE. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther. 2008;120:292-316.
5. Carey RM. Theodore Cooper Lecture: renal dopamine system: paracrine regulator of sodium homeostasis and blood pressure. Hypertension. 2001;38:297-302.
6. Wang ZQ, Siragy HM, Felder RA, Carey RM. Intrarenal dopamine production and distribution in the rat. Physiological control of sodium excretion. Hypertension. 1997;29(1 pt 2):228-234.
7. Kimbrough HM Jr, Vaughan ED Jr, Carey RM, Ayers CR. Effect of intrarenal angiotensin II blockade on renal function in conscious dogs. Circ Res. 1977;40:174-178.
8. Levens NR, Freedlender AE, Peach MJ, Carey RM. Control of renal function by intrarenal angiotensin II. Endocrinology. 1983;112:43-49.
9. Levens NR, Peach MJ, Carey RM. Role of the intrarenal renin-angiotensin system in the control of renal function. Circ Res. 1981;48:157-167.
10. Siragy HM, Howell NL, Peach MJ, Carey RM. Renal interstitial fluid angiotensin. Modulation by anesthesia, epinephrine, sodium depletion and renin inhibition. Hypertension. 1995;25:1021-1024.
11. Hunt MK, Ramos SP, Geary KM, Norling LL, Peach MJ, Gomez RA, et al. Colocalization and release of angiotensin and renin in renal cortical cells. Am J Physiol. 1992;263(3 pt 2):F363-F373.
12. Siragy HM, Howell NL, Peach MJ, Carey RM. Combined intrarenal blockade of the renin-angiotensin system in the conscious dog. Am J Physiol. 1990;258(3 pt 2):F522-F529.
13. Davisson RL, Ding Y, Stec DE, Catterall JF, Sigmund CD. Novel mechanism of hypertension revealed by cell-specific targeting of human angiotensinogen in transgenic mice. Physiol Genomics. 1999;1:3-9.
14. Navar LG, Kobori H, Prieto MC, Gonzalez-Villalobos RA. Intratubular renin-angiotensin system in hypertension. Hypertension. 2011;57:355-362.
15. Gwathmey TM, Alzayadneh EM, Pendergrass KD, Chappell MC. Novel roles of nuclear angiotensin receptors and signaling mechanisms. Am J Physiol Regul Integr Comp Physiol. 2012;302:R518-R530.
16. Abadir PM, Foster DB, Crowe M, Cooke CA, Rucker JJ, Jain A, Smith BJ,Burk TN, Cohn RD, Fedarko NS, Carey RM, O'Rourke B, Walston JD. Identification and characterization of a functional mitochondrial angiotensin system. Proc Natl Acad Sci USA. 2011;108:14849-14854.
17. Zhuo JAA, Alcom D, Aldred GP, MacGregor DP, Mendelsohn FA. The distribution of angiotensin II receptors. Hypertension. 1995;35: 155-163.
18. Ozono R, Wang ZQ, Moore AF, Inagami T, Siragy HM, Carey RM. Expression of the subtype 2 angiotensin (AT2) receptor protein in rat kidney. Hypertension. 1997;30:1238-1246.
19. Miyata N, Park F, Li XF, Cowley AW, Jr. Distribution of angiotensin AT1 and AT2 receptor subtypes in the rat kidney. Am J Physiol. 1999;277(3 pt 2):F437-F446.
20. Wang ZQ, Moore AF, Ozono R, Siragy HM, Carey RM. Immunolocalization of subtype 2 angiotensin II (AT2) receptor protein in rat heart. Hypertension. 1998;32:78-83.
21. Siragy HM, Carey RM. Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Hypertension. 1999;33:1237-1242.
22. Siragy HM, de Gasparo M, Carey RM. Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertension. 2000;35:1074-1077.
23. Carey RM, Howell NL, Jin X-H, Siragy HM. Angiotensin type 2 receptor-mediated hypotension in angiotensin type-1 receptor-blocked rats. Hypertension. 2001;38:1272-1277.
24. Katada J, Majima M. AT(2) receptor-dependent vasodilation is mediated by activation of vascular kinin generation under flow conditions. Br J Pharmacol. 2002;136:484-491.
25. Widdop RE, Matrougui K, Levy BI, Henrion D. AT2 receptor-mediated relaxation is preserved after long-term AT1 receptor blockade. Hypertension. 2002;40:516-520.
26. Hannan RE, Davis EA, Widdop RE. Functional role of angiotensin II AT2 receptor in modulation of AT1 receptor-mediated contraction in rat uterine artery: involvement of bradykinin and nitric oxide. Br J Pharmacol. 2003;140:987-995.
27. Batenburg WW, Garrelds IM, Bernasconi CC, Juillerat-Jeanneret L, van Kats JP, Saxena PR, Danser AH. Angiotensin II type 2 receptormediated vasodilation in human coronary microarteries. Circulation. 2004;109:2296-2301.
28. Bergaya S, Hilgers RH, Meneton P, Dong Y, Bloch-Faure M, Inagami T, Alhenc-Galas F, Levy BI, Boulanger CM. Flow-dependent dilation mediated by endogenous kinins requires angiotensin AT2 receptors. Circ Res. 2004;94:1623-1629.
29. Hiyoshi H, Yayama K, Takano M, Okamoto H. Stimulation of cyclic GMP production via AT2 and B2 receptors in the pressure-overloaded aorta after banding. Hypertension. 2004;43:1258-1263.
30. Yayama K, Horii M, Hiyoshi H, Takano M, Okamoto H, Kagota S, Kunitomo M. Up-regulation of angiotensin II type 2 receptor in rat thoracic aorta by pressure-overload. J Pharmacol Exp Ther. 2004;308:736-743.
31. Gauthier KM, Zhang DX, Edwards EM, Holmes B, Campbell WB. Angiotensin II dilates bovine adrenal cortical arterioles: role of endothelial nitric oxide. Endocrinology. 2005;146:3319-3324.
32. Perlegas D, Xie H, Sinha S, Somlyo AV, Owens GK. Ang II type 2 receptor regulates smooth muscle growth and force generation in late fetal mouse development. Am J Physiol Heart Circ Physiol. 2005;288:H96-H102.
33. Savoia C, Ebrahimian T, He Y, Gratton JP, Schiffrin EL, Touyz RM. Angiotensin II/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cyclic GMP-dependent protein kinase. J Hypertens. 2006;24:2417-2422.
34. Savoia C, Touyz RM, Volpe M, Schiffrin EL. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension. 2007;49:341-346.
35. Bosnyak S, Welungoda IK, Hallberg A, Alterman M, Widdop RE, Jones ES. Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. Br J Pharmacol. 2010;59:709-716.
36. Siragy HM, Carey RM. The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3',5'-monophosphate and AT1 receptor-mediated prostaglandin E2 production in conscious rats. J Clin Invest. 1996;97:1978-1982.
37. Siragy HM, Jaffa AA, Margolius HS, Carey RM. Renin-angiotensin system modulates renal bradykinin production. Am J Physiol Reg Int Comp Physiol. 1996;27:R1090-R1095.
38. Siragy HM, Carey RM. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest. 1997;100:264-269.
39. Siragy HM, Jaffa AA, Margolius HS. Bradykinin B2 receptor modulates renal prostaglandin E2 and nitric oxide. Hypertension. 1997;29:757-762.
40. Tsutsumi Y, Matsubara H, Masaki H, et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest. 1999;104:925-935.
41. Abadir PM, Carey RM, Siragy HM. Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2 receptor-null mice. Hypertension. 2003;42:600-604.
42. Berry C, Touyz R, Dominiczak AF, Webb RC, Johns DG. Angiotensin receptors: signaling, vascular pathophysiology and interactions with ceremide. Am J Physiol Heart Circ Physiol. 2001;281:H2337-H2365.
43. Widdop RE, Jones ES, Hannan RE, Gaspari TA. Angiotensin AT2 receptors:cardiovascular hope or hype Br J Pharmacol. 2003;140:809-824.
44. Bonnet F, Cooper ME, Carey RM, Casley D, Cao Z. Vascular expression of angiotensin type 2 receptor in the adult rat: influence of angiotnesin II infusion. J Hypertens. 2001;19:1075-1081.
45. Siragy HM, Inagami T, Ichiki T, Carey RM. Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci USA. 1999;96:6506-6510.
46. Padia SH, Howell NL, Siragy HM, Carey RM. Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat. Hypertension. 2006;47:537-544.
47. Padia SH, Kemp BA, Howell NL, Siragy HM, Fournie-Zaluski M-C, Roques BP, Carey RM. Intrarenal aminopeptidase N inhibition augments natriuretic responses to angiotensin III in angiotensin type 1 receptorblocked rats. Hypertension. 2007;49:625-630.
48. Padia SH, Kemp BA, Howell NL, Fournie-Zaluski M-C, Roques BP, Carey RM. Conversion of renal angiotensin II to angiotensin III is critical for AT2 receptor-mediated natriuresis in rats. Hypertension. 2008;51:460-465.
49. Bosnyak S, Jones ES, Christopoulos A, Aguilar MI, Thomas WG, Widdop RE. Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci (Lond). 2011;121:297-303.
50. van Esch JH, Oosterveer CR, Batenburg WW, van Veghel R, Jan Danser AH. Effects of angiotensin II and its metabolites in the rat coronary vascular bed: is angiotensin III the preferred ligand of the angiotensin AT2 receptoR Eur J Pharmacol. 2008;588:286-293.
51. Yatabe J, Yoneda M, Yatabe MS, Watanabe T, Felder RA, Jose PA, Sanada H. Angiotensin III stimulates aldosterone secretion from the adrenal gland partially via angiotensin II type 2 receptor but not angiotensin II type 1 receptor. Endocrinology. 2011;152:1582-1588.
52. Kemp BA, Bell JF, Rottkamp DM, Howell NL, Shao W, Navar LG, Padia SH, Carey RM. Intrarenal angiotensin III is the predominant agonist for proximal tubule angiotensin type 2 receptors. Hypertension. 2012;60:387-395.
53. Yang J, Chen C, Ren H, Han Y, He D, Zhou L, Hopfer U, Jose PA, Aeng C. Angiotensin II AT2 receptor decreases AT1 receptor expression and function via nitric oxide/cGMP/Sp1 in renal proximal tubule cells from Wistar-Kyoto rats. J Hypertens. 2012;30:1176-1184.
54. Herrera M, Garvin JL. Angiotensin II stimulates thick ascending limb NO production via AT(2) receptors and Akt1-dependent nitric oxide synthase 3 (NOS3) activation. J Biol Chem. 2010;285:14932-14940.
55. Hong NJ, Garvin JL. Angiotensin II type 2 receptor-mediated inhibition of NaCl absorption is blunted in thick ascending limbs from Dahl salt-sensitive rats. Hypertension. 2012;60:765-769.
56. Hughes JM, Beck TR, Rose CE Jr, Carey RM. Selective dopamine-1 receptor stimulation produces natriuresis by a direct tubular action. J Hypertens Suppl. 1986;4:S106-S108.
57. Carey RM, Hughes JM. Selective renal dopamine-1 receptor stimulation in man. Clin Exp Hypertens. 1987;9:1009-1020.
58. Hughes JM, Ragsdale NV, Felder RA, Chevalier RL, Keng B, Carey RM. Diuresis and natriuresis during continuous dopamine-1 receptor stimulation. Hypertension. 1988;11:169-174.
59. Hughes JM, Beck TR, Rose CE Jr, Carey. The effect of selective dopamine-1 receptor stimulation on renal and adrenal function. J Clin Endocrinol Metab. 1988;66:518-525.
60. Ragsdale NV, Lynd M, Chevalier RL, Felder RA, Peach MJ, Carey RM. Selective peripheral dopamine-1 receptor stimulation. Differential responses to sodium loading and depletion in humans. Hypertension. 1990;15(6 pt 2):914-921.
61. Carey RM, Stote RM, Dubb JW, Townsend LH, Rose CE Jr, Kaiser DL. Selective peripheral dopamine-1 receptor stimulation with fenoldopam in human essential hypertension. J Clin Invest. 1984;74:2198-2207.
62. Siragy HM, Felder RA, Howell NL Chevalier RL, Peach MJ, Carey RM. Intrarenal DA acts at the dopamine-1 receptor to control renal function. J Hypertens Suppl. 1988;6:S479-S481.
63. Siragy HM, Felder RA, Howell NL, Chevalier RL, Peach MJ, Carey RM. Evidence that intrarenal dopamine acts as a paracrine substance at the renal tubule. Am J Physiol Renal Physiol. 1989;257:F469-F477.
64. Wang ZQ, Felder RA, Carey RM. Selective inhibition of the renal dopamine subtype D1A receptor induces antinatriuresis in conscious rats. Hypertension. 1999;33:504-510.
65. Carey RM, Van Loon GR, Baines AD, Ortt EM. Decreased plasma and urinary dopamine during dietary sodium depletion in man. J Clin Endocrinol Metab. 1981;52:903-909.
66. Zhang M-Z, Yao B, Wang S, Fan X, Wu G, Yang H, Yin H, Yang S, Harris RC. Intrarenal dopamine deficiency leads to hypertension and decreased longevity in mice. J Clin Invest. 2011;2845-2854.
67. O'Connell DP, Botkin SJ, Ramos SI, Sibley DR, Ariano MA, Felder RA, Carey RM. Localization of the dopamine D1A receptor protein in rat kidneys. Am J Physiol Renal Physiol. 1995;F1185-F1197.
68. Ozono R, O'Connell DP, Vaughan C, Botkin SJ, Walk SF, Felder RA, Carey RM. Expression of the subtype 1A dopamine receptor in the rat heart. Hypertension. 1996;27:693-703.
69. Ozono R, O'Connell DP, Wang ZQ, Moore AF, Sanada H, Felder RA, Carey RM. Localization of the dopamine D1A receptor protein in rat kidneys. Am J Physiol Renal Physiol. 1995;268(6 pt 2):F1185-F1197.
70. O'Connell DP, Aherne AM, Lane E, Felder RA, Carey RM. Detection of dopamine receptor D1A subtype-specific mRNA in rat kidney by in situ amplification. Am J Physiol. 1998;274(1 pt 2):F232-F241.
71. Salomone LJ, Howell NL, McGrath HE, Kemp BA, Keller SR, Gildea JJ, Felder RA, Carey RM. Intrarenal dopamine D1-like receptor stimulation induces natriuresis via an angiotensin type-2 receptor mechanism. Hypertension. 2007;49:155-161.
72. Padia SH, Kemp BA, Howell NL, Keller SR, Gildea JJ, Carey RM. Mechanisms of dopamine D(1) and angiotensin type 2 receptor interaction in natriuresis. Hypertension. 2012;59:437-445.
73. Brismar H, Asghar M, Carey RM, Greengard P, Aperia A. Dopamineinduced recruitment of dopamine D1 receptors to the plasma membrane. Proc Natl Acad Sci USA. 1998;95:5573-5578.
74. Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, Conti S, Rottoli D, Longaretti L, Cassis P, Morgi M, Coffman TM, Remuzzi G. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest. 2009;119:524-530.
75. Zhang MZ, Yao B, Wang S, Fan X, Wu G, Yang H, Yin H, Yang S, Harris RC. Intrarenal dopamine deficiency leads to hypertension and decreased longevity in mice. J Clin Invest. 2011;121:2845-2854.
76. Abadir PM, Walston JD, Carey RM. Subcellular characteristics of functional intracellular renin-angiotensin systems. Peptides. 2012;38: 437-445.